Delivery Order SPE2DB22D3016-SPE2DB25FBEK7
- Not listed
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 3mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order carries a ceiling value of $6,616.74 and is scheduled for completion by August 21, 2025. The award was made on a competitive, non-set-aside basis to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $1,790.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order valued at $8,895.79 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-competed, firm fixed-price delivery order has a completion date of August 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $18,711.54 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HYPERRAB 300 Unit/ML (1 unit). This firm fixed-price delivery order, with completion scheduled for August 28, 2025, represents a competitive award with no set-aside designation. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion...
- This delivery order, awarded on August 7, 2025, to AmerisourceBergen Drug Corp represents a $8,954.05 firm fixed-price procurement of HYPERRAB 300 Unit/mL rabies immunoglobulin. The award was issued by the Medical Supply Chain, a Defense Logistics Agency entity responsible for pharmaceutical and medical supply procurement to support military and federal healthcare systems. As a child order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBEK7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product commonly used for post-exposure prophylaxis. This firm fixed price delivery order, valued at $10,744.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for rabies immunoglobulin reflects the company's ongoing role as a primary pharmaceutical supplier supporting military healthcare needs through the DLA's pharmaceutical supply chain. The product's immediate completion timeline indicates this is fulfilling an urgent medical supply requirement for military or federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 8/8/25 |